glp-1 obesity drug news updates New research is challenging long-held assumptions about drugs in weight loss treatments. A different approach may be emerging.⁠ ⁠ Click the link in bio to read the full story New research is challenging long-held

GLP-1s are trending as the next big thing in weight loss

Yet, data on their safety and clinical utility during these reproductive windows remain limited

Discover how Retatrutide works through its triple-pathway mechanism (GLP-1, GIP, glucagon), how it affects metabolism, and when results may begin.

They click buy

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.